Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ROLLIG C. STEFFEN B. ALAKEL N. HERBST R. NOPPENEY R. HANOUN M. RACIL Z. SCHAFER-ECKART K. KRAMER A. NEUBAUER A. BALDUS C. D. SCHLIEMANN C. KAUFMANN M. MERTOVA J. JOST E. NIEMANN D. NOVAK J. KRAUSE S. W. SCHOLL S. HELD G. PARMENTIER S. B. SZOTKOWSKI T. ZAK P. RANK A. WASS M. BUSKE S. KRAMER M. FIEBIG F. HAAKE A. SCHETELIG J. PLATZBECKER U. THIEDE C. MULLER-TIDOW C. BERDEL W. E. SERVE H. EHNINGER G. MAYER Jiří BORNHAUSER M.

Year of publication 2020
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Double induction using two subsequent 7+3 regimens of cytarabine plus anthracycline is commonly performed in AML patients with an adequate performance status in order to maximize dose intensity upfront. However, for patients with a good early response at day 15 of first induction, there is no prospective randomized evidence on the necessity or value of a second induction cycle. In order to answer the question if good responders of the first 7+3 induction could be spared a second induction cycle, we set up randomized-controlled SAL DaunoDouble trial. The study prospectively assesses the outcome of patients with a good early response with respect to the number of induction cycles (single versus double). We assumed non-inferiority of single induction in terms of complete remission (CR/CRi) rate, based on a margin of 7.5%. Here, we present the results of the planned interim analysis.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.